Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Debut Biotech, a company innovating new molecules through advanced biotechnology, is partnering with Image Skincare to launch ...

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

The U.S. inked Technology Prosperity Deals (TPD) with Japan and South Korea with an eye toward spurring collaboration on AI, ...

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Edesa Biotech has announced positive results from a Phase III clinical trial of its drug candidate, paridiprubart (EB05), for ...

Welcome to the Fierce Biotech Graveyard, a yearly ritual where we remember all the biotechs we lost in 2025. While we're ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...